Outcomes after HCT of recipients receiving plerixafor mobilized PBSCs compared with control recipients receiving G-CSF mobilized PBSCs from the CIBMTR
| Outcome . | MAC PLEX (n = 30) . | MAC CIBMTR (n = 99) . | P . | RIC PLEX (n = 33) . | RIC CIBMTR (n = 73) . | P . |
|---|---|---|---|---|---|---|
| Neutrophil engraftment by day +100, % | 100 | 100 | — | 100 | 100 | — |
| Platelet engraftment by day +100, % | 100 | 98 | — | 97 | 94 | .530 |
| Day 100 cumulative incidence of grades 2-4 acute GVHD (range) | 53 (35-71) | 32 (23-42) | .045 | 18 (7-33) | 23 (14-34) | .546 |
| Day 100 cumulative incidence of grades 3-4 acute GVHD (range) | 17 (6-32) | 5 (2-10) | .110 | 3 (0-12) | 7 (2-14) | .369 |
| 1-y cumulative incidence of chronic GVHD (range) | 52 (33-70) | 51 (41-60) | .913 | 39 (23-57) | 40 (29-52) | .933 |
| 1-y cumulative incidence of disease relapse (range) | 30 (15-48) | 35 (26-45) | .586 | 30 (16-47) | 47 (35-58) | .106 |
| 1-y cumulative incidence of NRM (range) | 17 (6-32) | 15 (9-23) | .847 | 6 (1-17) | 7 (2-14) | .879 |
| 1-y progression-free survival (range) | 53 (36-71) | 49 (40-59) | .712 | 64 (47-79) | 47 (35-58) | .095 |
| 1-y OS (range) | 63 (46-79) | 66 (56-75) | .816 | 70 (53-84) | 63 (52-74) | .495 |
| 1-y GRFS (range) | 23 (10-40) | 30 (22-40) | .439 | 39 (24-56) | 29 (19-40) | .289 |
| Outcome . | MAC PLEX (n = 30) . | MAC CIBMTR (n = 99) . | P . | RIC PLEX (n = 33) . | RIC CIBMTR (n = 73) . | P . |
|---|---|---|---|---|---|---|
| Neutrophil engraftment by day +100, % | 100 | 100 | — | 100 | 100 | — |
| Platelet engraftment by day +100, % | 100 | 98 | — | 97 | 94 | .530 |
| Day 100 cumulative incidence of grades 2-4 acute GVHD (range) | 53 (35-71) | 32 (23-42) | .045 | 18 (7-33) | 23 (14-34) | .546 |
| Day 100 cumulative incidence of grades 3-4 acute GVHD (range) | 17 (6-32) | 5 (2-10) | .110 | 3 (0-12) | 7 (2-14) | .369 |
| 1-y cumulative incidence of chronic GVHD (range) | 52 (33-70) | 51 (41-60) | .913 | 39 (23-57) | 40 (29-52) | .933 |
| 1-y cumulative incidence of disease relapse (range) | 30 (15-48) | 35 (26-45) | .586 | 30 (16-47) | 47 (35-58) | .106 |
| 1-y cumulative incidence of NRM (range) | 17 (6-32) | 15 (9-23) | .847 | 6 (1-17) | 7 (2-14) | .879 |
| 1-y progression-free survival (range) | 53 (36-71) | 49 (40-59) | .712 | 64 (47-79) | 47 (35-58) | .095 |
| 1-y OS (range) | 63 (46-79) | 66 (56-75) | .816 | 70 (53-84) | 63 (52-74) | .495 |
| 1-y GRFS (range) | 23 (10-40) | 30 (22-40) | .439 | 39 (24-56) | 29 (19-40) | .289 |